MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

<jats:p>Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, op...

Full description

Bibliographic Details
Main Authors: Stopfer, Lauren E, Rettko, Nicholas J, Leddy, Owen, Mesfin, Joshua M, Brown, Eric, Winski, Shannon, Bryson, Bryan, Wells, James A, White, Forest M
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Language:English
Published: Proceedings of the National Academy of Sciences 2023
Online Access:https://hdl.handle.net/1721.1/147778

Internet

https://hdl.handle.net/1721.1/147778

Similar Items